In the November 28, 2017 Journal of the American Medical Association (JAMA), Dr. Carlos Zarate Jr. at the National Institute of Mental Health states "There have now been many published clinical trails, and most of them have found that it (KETAMINE) is effective in treatment-resistant depression. The response and remission rates within a very short period of time are pretty prominent. It is efficacious even in treatment-resistant depression, meaning patients that have failed multiple antidepressants, and in many cases electroconvulsive therapy. And ketamine is efficacious in treatment-resistant bipolar depression. Further clinical research suggests that ketamine does have-although this is preliminary-very rapid antisuicidal efficacy and seems to have an effect on anhedonia."